MedTrace Logo

Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders

NCT07261891 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-12-03

No results posted yet for this study

Summary

The investigators want to study the JAK-inhibitors and their impact on the immune system and evaluate the potential of a gene-therapeutic strategy

Conditions

  • Primary Immunodeficiency Diseases (PID)

Interventions

DIAGNOSTIC_TEST

blood sampling

Blood/serum samples will be collected during routine clinical visits at the time of planned peripheral venous blood sampling. Samples will be processed and either used immediately (flow cytometry-based cell sorting, gDNA extraction, in vitro functional assays, primary cell culture or single-cell applications) or stored for later analysis.

Sponsors & Collaborators

  • Research Foundation - Flanders (Fonds Wetenschappelijk Onderzoek)

    collaborator OTHER

  • prof. dr. Rik Schrijvers

    lead OTHER

Principal Investigators

  • Rik Schrijvers, MD, PhD · UZ Leuven

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-21
Primary Completion
2028-12-01
Completion
2030-12-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07261891 on ClinicalTrials.gov